XALKORI (crizotinib)
ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·ANAPLASTIC LYMPHOMA KINASE POSITIVE NON-SMALL CELL LUNG CANCER·+3
Parke-Davis Pfizer
Indication
ALK-positive inflammatory myofibroblastic tumor
ALK-positive inflammatory myofibroblastic tumor (IMT) is a rare mesenchymal neoplasm characterized by intermediate biological potential, locally invasive behavior, and a tendency for local recurrence. Read more about ALK-positive inflammatory myofibroblastic tumor
2 drugs 2 manufacturers
Drugs that treat it
Common ALK-positive inflammatory myofibroblastic tumor therapies.
XALKORI (crizotinib)
ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·ANAPLASTIC LYMPHOMA KINASE POSITIVE NON-SMALL CELL LUNG CANCER·+3
Laboratories Div
Filter & compare in the drug finder →Opens the drug finder with ALK-positive inflammatory myofibroblastic tumor preselected.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonALK-positive inflammatory myofibroblastic tumor (IMT) is a rare mesenchymal neoplasm characterized by intermediate biological potential, locally invasive behavior, and a tendency for local recurrence.
Pathophysiologically, it is defined by clonal rearrangements involving the anaplastic lymphoma kinase (*ALK*) gene at chromosome 2p23, leading to constitutive tyrosine kinase activation, myofibroblastic spindle cell proliferation, and a prominent reactive inflammatory infiltrate of lymphocytes and plasma cells.
Although it predominantly arises in children and young adults, it can affect patients of any age and develop in virtually any anatomical site, most frequently within the lungs, abdominopelvic region, mesentery, and retroperitoneum.
Patients typically present with mass-related local symptoms or systemic inflammatory manifestations such as fever, weight loss, and anemia driven by cytokine production.
- nih.gov
ALK-positive inflammatory myofibroblastic tumor (IMT) is a rare mesenchymal neoplasm characterized by intermediate biological potential, locally invasive behavior, and a tendency for local recurrence Pathophysiologically, it is defined by clonal rearrangements involving the anaplastic lymphoma kinase (*ALK*) gene at chromosome 2p23, leading to constitutive tyrosine kinase activation, myofibroblastic spindle cell proliferation, and a prominent reactive inflammatory infiltrate of lymphocytes and p...
- nih.gov
ALK-positive inflammatory myofibroblastic tumor (IMT) is a rare mesenchymal neoplasm characterized by intermediate biological potential, locally invasive behavior, and a tendency for local recurrence Pathophysiologically, it is defined by clonal rearrangements involving the anaplastic lymphoma kinase (*ALK*) gene at chromosome 2p23, leading to constitutive tyrosine kinase activation, myofibroblastic spindle cell proliferation, and a prominent reactive inflammatory infiltrate of lymphocytes and p...
- nih.gov
Pathophysiologically, it is defined by clonal rearrangements involving the anaplastic lymphoma kinase (*ALK*) gene at chromosome 2p23, leading to constitutive tyrosine kinase activation, myofibroblastic spindle cell proliferation, and a prominent reactive inflammatory infiltrate of lymphocytes and plasma cells
- frontiersin.org
Although it predominantly arises in children and young adults, it can affect patients of any age and develop in virtually any anatomical site, most frequently within the lungs, abdominopelvic region, mesentery, and retroperitoneum
- jpatholtm.org
Although it predominantly arises in children and young adults, it can affect patients of any age and develop in virtually any anatomical site, most frequently within the lungs, abdominopelvic region, mesentery, and retroperitoneum
- mypathologyreport.ca
Patients typically present with mass-related local symptoms or systemic inflammatory manifestations such as fever, weight loss, and anemia driven by cytokine production
- turkjpath.org
Patients typically present with mass-related local symptoms or systemic inflammatory manifestations such as fever, weight loss, and anemia driven by cytokine production
Personalize your experience
Follow ALK-positive inflammatory myofibroblastic tumor and get updates as they land.
Create a free account
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.